These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Spike-specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-convalescent individuals. Zhang J; Wu Q; Liu Z; Wang Q; Wu J; Hu Y; Bai T; Xie T; Huang M; Wu T; Peng D; Huang W; Jin K; Niu L; Guo W; Luo D; Lei D; Wu Z; Li G; Huang R; Lin Y; Xie X; He S; Deng Y; Liu J; Li W; Lu Z; Chen H; Zeng T; Luo Q; Li YP; Wang Y; Liu W; Qu X Nat Microbiol; 2021 Jan; 6(1):51-58. PubMed ID: 33199863 [TBL] [Abstract][Full Text] [Related]
44. Patients receiving hemodialysis do not lose SARS-CoV-2 antibodies more rapidly than non-renal controls: a prospective cohort study. Parshina E; Zulkarnaev A; Tolkach A; Ivanov A; Kislyy P; Gaipov A Ren Fail; 2022 Dec; 44(1):392-398. PubMed ID: 35220855 [TBL] [Abstract][Full Text] [Related]
45. Divergent SARS-CoV-2-specific T- and B-cell responses in severe but not mild COVID-19 patients. Oja AE; Saris A; Ghandour CA; Kragten NAM; Hogema BM; Nossent EJ; Heunks LMA; Cuvalay S; Slot E; Linty F; Swaneveld FH; Vrielink H; Vidarsson G; Rispens T; van der Schoot E; van Lier RAW; Ten Brinke A; Hombrink P Eur J Immunol; 2020 Dec; 50(12):1998-2012. PubMed ID: 33073359 [TBL] [Abstract][Full Text] [Related]
46. Low anti-SARS-CoV-2 S antibody levels predict increased mortality and dissemination of viral components in the blood of critical COVID-19 patients. Martin-Vicente M; Almansa R; Martínez I; Tedim AP; Bustamante E; Tamayo L; Aldecoa C; Gómez JM; Renedo G; Berezo JÁ; Cedeño JA; Mamolar N; García Olivares P; Herrán-Monge R; Cicuendez R; Enríquez P; Ortega A; Jorge N; Doncel C; de la Fuente A; Bustamante-Munguira J; Muñoz-Gómez MJ; González-Rivera M; Puertas C; Más V; Vázquez M; Pérez-García F; Rico-Feijoo J; Martín S; Motos A; Fernandez-Barat L; Eiros JM; Dominguez-Gil M; Ferrer R; Barbé F; Trapiello W; Kelvin DJ; Bermejo-Martin JF; Resino S; Torres A J Intern Med; 2022 Feb; 291(2):232-240. PubMed ID: 34611927 [TBL] [Abstract][Full Text] [Related]
47. Potent SARS-CoV2-specific T-cell response in asymptomatic hemodialysis patients with hidden COVID-19 infection history. Etemadi J; Motavalli R; Mirghaffari SA; Soltani-Zangbar MS; Hajivalili M; Ahmadian Heris J; Niknafs B; Zununi S; Sadeghi M; Rasi Hashemi S; Tayebi Khosroshahi H; Yousefi M J Clin Lab Anal; 2023 Mar; 37(5):e24863. PubMed ID: 36941528 [TBL] [Abstract][Full Text] [Related]
48. A comprehensive assessment of long-term SARS-CoV-2-specific adaptive immune memory in convalescent COVID-19 Solid Organ Transplant recipients. Favà A; Donadeu L; Jouve T; Gonzalez-Costello J; Lladó L; Santana C; Toapanta N; Lopez M; Pernin V; Facundo C; Cabañas NS; Thaunat O; Crespo M; Llinàs-Mallol L; Revuelta I; Sabé N; Rombauts A; Calatayud L; Ardanuy C; Esperalba J; Fernandez C; Lozano JJ; Preyer R; Strecker K; Couceiro C; García-Romero E; Cachero A; Meneghini M; Torija A; Le Quintrec M; Melilli E; Cruzado JM; Polo C; Moreso F; Crespo E; Bestard O Kidney Int; 2022 May; 101(5):1027-1038. PubMed ID: 35124011 [TBL] [Abstract][Full Text] [Related]
49. Seroconversion in septic ICU patients presenting with COVID-19: necessary but not sufficient. Conti F; Oriol G; Cheynet V; Tardiveau C; Cerrato E; Rimmelé T; Lukaszewicz AC; Argaud L; Cour M; ; Brengel-Pesce K; Venet F; Monneret G Arch Med Res; 2021 Nov; 52(8):850-857. PubMed ID: 34538689 [TBL] [Abstract][Full Text] [Related]
50. Chemokines, soluble PD-L1, and immune cell hyporesponsiveness are distinct features of SARS-CoV-2 critical illness. Morrell ED; Bhatraju PK; Sathe NA; Lawson J; Mabrey L; Holton SE; Presnell SR; Wiedeman A; Acosta-Vega C; Mitchem MA; Liu T; Chai XY; Sahi S; Brager C; Orlov M; Sakr SS; Sader A; Lum DM; Koetje N; Garay A; Barnes E; Cromer G; Bray MK; Pipavath S; Fink SL; Evans L; Long SA; West TE; Wurfel MM; Mikacenic C Am J Physiol Lung Cell Mol Physiol; 2022 Jul; 323(1):L14-L26. PubMed ID: 35608267 [TBL] [Abstract][Full Text] [Related]
51. Kinetics of CD169, HLA-DR, and CD64 expression as predictive biomarkers of SARS-CoV2 outcome. Gatti A; Fassini P; Mazzone A; Rusconi S; Brando B; Mistraletti G J Anesth Analg Crit Care; 2023 Mar; 3(1):6. PubMed ID: 37386613 [TBL] [Abstract][Full Text] [Related]
53. SARS-CoV-2 infection in dialysis and kidney transplant patients: immunological and serological response. Alberici F; Affatato S; Moratto D; Mescia F; Delbarba E; Guerini A; Tedesco M; Burbelo PD; Zani R; Castagna I; Gallico A; Tonoli M; Venturini M; Roccaro AM; Giacomelli M; Cohen JI; Giustini V; Dobbs K; Su HC; Fiorini C; Quaresima V; Viola FB; Vizzardi V; Gaggiotti M; Bossini N; Gaggia P; Badolato R; Notarangelo LD; Chiarini M; Scolari F J Nephrol; 2022 Apr; 35(3):745-759. PubMed ID: 35067905 [TBL] [Abstract][Full Text] [Related]
54. Classical monocytes-low expressing HLA-DR is associated with higher mortality rate in SARS-CoV-2+ young patients with severe pneumonia. Henao-Agudelo JS; Ayala S; Badiel M; Zea-Vera AF; Matta Cortes L Heliyon; 2024 Jan; 10(2):e24099. PubMed ID: 38268832 [TBL] [Abstract][Full Text] [Related]
55. Along with PaO2/FiO2 ratio and lymphopenia, low HLA-DR monocytes are the only additional parameter that independently predicts the clinical course of undifferentiated SARS-CoV-2 patients in emergency departments. Lafon T; Chapuis N; Guerin E; Daix T; Otranto M; Boumediene A; Jeannet R; Fontenay M; Henri Hani K; Vignon P; Monneret G; François B; Jean-Philippe J; Feuillard J J Leukoc Biol; 2024 May; 115(6):1131-1142. PubMed ID: 38366559 [TBL] [Abstract][Full Text] [Related]
57. Overlapping but Disparate Inflammatory and Immunosuppressive Responses to SARS-CoV-2 and Bacterial Sepsis: An Immunological Time Course Analysis. Loftus TJ; Ungaro R; Dirain M; Efron PA; Mazer MB; Remy KE; Hotchkiss RS; Zhong L; Bacher R; Starostik P; Moldawer LL; Brakenridge SC Front Immunol; 2021; 12():792448. PubMed ID: 34956225 [TBL] [Abstract][Full Text] [Related]
58. Joint modeling of monocyte HLA-DR expression trajectories predicts 28-day mortality in severe SARS-CoV-2 patients. Baudemont G; Tardivon C; Monneret G; Cour M; Rimmelé T; Garnier L; Yonis H; Richard JC; Coudereau R; Gossez M; Wallet F; Delignette MC; Dailler F; Buisson M; Lukaszewicz AC; Argaud L; Laouenan C; Bertrand J; Venet F; CPT Pharmacometrics Syst Pharmacol; 2024 Jul; 13(7):1130-1143. PubMed ID: 38837680 [TBL] [Abstract][Full Text] [Related]
59. Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients. Mansi L; Spehner L; Daguindau E; Bouiller K; Almotlak H; Stein U; Bouard A; Kim S; Klajer E; Jary M; Meynard G; Vienot A; Nardin C; Bazan F; Lepiller Q; Westeel V; Adotévi O; Borg C; Kroemer M Eur J Cancer; 2021 Jun; 150():1-9. PubMed ID: 33882374 [TBL] [Abstract][Full Text] [Related]
60. Case report: Understanding the impact of persistent tissue-localization of SARS-CoV-2 on immune response activity Lau MC; Yi Y; Goh D; Cheung CCL; Tan B; Lim JCT; Joseph CR; Wee F; Lee JN; Lim X; Lim CJ; Leow WQ; Lee JY; Ng CCY; Bashiri H; Cheow PC; Chan CY; Koh YX; Tan TT; Kalimuddin S; Tai WMD; Ng JL; Low JG; Lim TKH; Liu J; Yeong JPS Front Immunol; 2022; 13():978760. PubMed ID: 36172383 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]